Learn More
BACKGROUND Efalizumab (anti-CD11a), a humanized monoclonal antibody, blocks multiple T-cell-dependent functions implicated in the pathogenesis of psoriasis, including T-cell activation, migration to(More)
BACKGROUND Health-related quality of life (HRQOL) and other patient-reported outcomes (PROs) are important in evaluating the impact of psoriasis and its treatment. OBJECTIVES To assess the impact(More)
BACKGROUND Drug survival is a marker for treatment sustainability in chronic diseases such as psoriasis. OBJECTIVE The aim of these analyses was to assess survival of biologic treatments in the(More)
BACKGROUND Poor adherence to topical therapy in psoriasis remains an issue; it is associated with poor clinical outcomes, reduced quality of life and increased costs. Treatment-related factors(More)